Utilizing Isolate Of Tissue Or Organ As Binding Agent Patents (Class 436/503)
  • Patent number: 9005907
    Abstract: Immunohistochemical methods and compositions for the typing of molecular subgroups of medulloblastomas are provided. The methods comprise determining a protein expression profile for a sample obtained from a medulloblastoma by detecting expression of GAB1, filamin A, or at least two biomarker proteins selected from the group consisting of ?-catenin, YAP1, GAB1, and filamin A, and typing the medulloblastoma as a WNT pathway tumor, a SHH pathway tumor, or a non-WNT/non-SHH tumor based on this protein expression profile. Kits for typing a medulloblastoma according to these three molecular subgroups are provided. The kits comprise at least two antibodies, wherein each of said antibodies specifically binds to a distinct biomarker protein selected from the group consisting of ?-catenin, YAP1, GAB1, and filamin A, and can optionally comprise one or more of instructions for use, reagents for detecting antibody binding to one or more of said biomarker proteins, and one or more positive control samples.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: April 14, 2015
    Assignee: St. Jude Children's Research Hospital
    Inventor: David Ellison
  • Patent number: 9005982
    Abstract: The present disclosure is generally related to pulmonary autoantigens. The disclosure provides methods and kits for assessing whether a subject has or is predisposed to interstitial lung disease. Additionally the present disclosure provides methods of treatment and animal models of interstitial lung disease.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: April 14, 2015
    Assignee: The Regents of the University of California
    Inventors: Mark S. Anderson, Anthony K. Shum
  • Patent number: 8980638
    Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: March 17, 2015
    Assignee: University of Massachusetts
    Inventor: Zhong Jiang
  • Patent number: 8980567
    Abstract: Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: March 17, 2015
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Lidia L. Demchyshyn, Hong Wang
  • Patent number: 8969023
    Abstract: Aspects of the invention relate to methods and compositions for treating Alzheimer's disease (AD). In some embodiments, the invention provides methods for screening and identifying compounds that selectively inhibit the targeting of the insulin-Akt signaling pathway by A? oligomers.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: March 3, 2015
    Assignee: Eleanore Bennett Charitable Trust #2
    Inventor: Henry W. Querfurth
  • Patent number: 8968706
    Abstract: The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: March 3, 2015
    Inventor: Robert I. Henkin
  • Patent number: 8956811
    Abstract: The present invention relates to novel antibodies that bind specifically to human Notch 3 and their use in the detection and/or diagnosis of Notch 3 related diseases, such as cancer. The present invention also includes nucleic acids encoding these novel antibodies, vectors and cell lines harboring the nucleic acids, and kits comprising the antibodies for use in the detection and diagnosis.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: February 17, 2015
    Assignee: Genentech Inc.
    Inventors: Kang Li, Sek Chung Fung, Zhengbin Yao
  • Patent number: 8945857
    Abstract: The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: February 3, 2015
    Inventor: John Schrader
  • Patent number: 8822168
    Abstract: The present invention includes assays and kits for detecting the assembly of an RNA binding protein-RNA complex and for detecting the activity of an RNA binding protein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: September 2, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Gideon Dreyfuss, Lili Wan, Elizabeth Ottinger
  • Patent number: 8753828
    Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: June 17, 2014
    Inventors: Theresa O'Keefe, Paul Ponath
  • Patent number: 8741586
    Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: June 3, 2014
    Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'Hebron
    Inventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
  • Patent number: 8735171
    Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: May 27, 2014
    Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM)
    Inventors: Hugues De The, Valerie Lallemand-Breitenbach
  • Patent number: 8703441
    Abstract: The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment or diagnosis of cancer progression. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: April 22, 2014
    Assignee: Alper Biotech, LLC
    Inventor: Özge Alper
  • Patent number: 8691231
    Abstract: Disclosed are pharmaceutical preparations for, and methods for determining, appropriate and effective treatment with therapeutic agents comprising a single species of anti-EGFR monoclonal antibody or therapeutic agents comprising a plurality of species of such antibodies, as well as kits useful for making such determinations.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: April 8, 2014
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Raghida Bukhalid, Ulrik Nielsen, Shannon Werner, Jeffrey David Kearns
  • Patent number: 8685666
    Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 1, 2014
    Assignee: The Board of Trustees of Southern Illinois University
    Inventor: Deliang Cao
  • Patent number: 8673572
    Abstract: The invention encompasses methods and kits used in the identification of invasive glioblastoma based upon the expression of Akt1, Akt2, and Akt3. The methods and kits also allow prediction of disease outcome and staging of patients with regard to therapy.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: March 18, 2014
    Assignee: The Translational Genomics Research Institute
    Inventor: Nhan Tran
  • Patent number: 8642283
    Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: February 4, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventor: Robert T. Abraham
  • Patent number: 8628931
    Abstract: This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: January 14, 2014
    Assignee: George Mason Intellectual Properties, Inc.
    Inventors: Lance A. Liotta, Emanuel F. Petricoin, III, Virginia Espina
  • Patent number: 8623605
    Abstract: The invention provides a method of diagnosis of a spongiform encephalopathy in a diagnostic sample of a valid body tissue taken from a subject, which comprises detecting an increased proteolytic activity in the diagnostic sample, compared with a sample from a control subject.
    Type: Grant
    Filed: May 29, 2007
    Date of Patent: January 7, 2014
    Assignee: Electrophoretics Limited
    Inventors: Ian Hugo Pike, Malcolm Andrew Ward, Darragh Patrick William O'Brien
  • Patent number: 8623666
    Abstract: Herein is reported an antibody that specifically binds to human EPO receptor, wherein the antibody binds to EPO receptor fragment LPGPGGSVDIV (SEQ ID NO: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kD.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: January 7, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Jarsch, Olaf Mundigl
  • Patent number: 8617906
    Abstract: The identification of triptolide target molecules is described. Also described are methods of screening triptolide-related compounds for binding to these molecules, including screening for enhanced and/or selective binding, and expression analysis of the target molecules in normal and in diseased tissue.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: December 31, 2013
    Assignee: Pharmagenesis, Inc.
    Inventors: John M. Fidler, John H. Musser
  • Patent number: 8617820
    Abstract: An immunoassay reagent is provided which comprises an analyte binding agent in a diluent, and a glycosaminoglycan in an amount sufficient to reduce non-specific binding in an assay of a sample for the analyte. Provided is such an immunoassay reagent in which the analyte is troponin I, the analyte binding agent is a biotinylated anti-troponin I antibody, and the glycosaminoglycan is chondroitin sulfate. A sample composition is also provided which comprises a sample to be assayed for the presence of an analyte, an analyte binding agent, and a glycosaminoglycan other than heparin. Further provided is a method of detecting an analyte in a sample, in which non-specific binding is reduced in the method using a glycosaminoglycan.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 31, 2013
    Assignee: Ortho-Clinical Diagnostics, Inc.
    Inventors: Banumathi Sankaran, Sheryl S. Sullivan, Darrell C. Haynes, Philip C. Hosimer, Graham Yearwood
  • Patent number: 8603765
    Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: December 10, 2013
    Assignee: Biocare Medical, LLC.
    Inventor: David Tacha
  • Patent number: 8569448
    Abstract: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression. (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: October 29, 2013
    Assignee: Grace Laboratories, LLC
    Inventor: Svetlana A. Dambinova
  • Patent number: 8563249
    Abstract: Compositions and methods that use the body's natural secretory immune system in a new way against steroid hormone responsive tumors of the breast and prostate, as well as other glandular/mucus epithelial tissues such as colon, ovary, endometrium, kidney, bladder, stomach, pancreas and secretory pituitary gland are provided. Also provided are new ways of identifying carcinogenic, or potentially carcinogenic, bacteria in a tissue or body fluid to provide better anti-cancer therapies and preventatives than have been available previously.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: October 22, 2013
    Assignee: Signe BioPharma Inc.
    Inventor: David A. Sirbasku
  • Publication number: 20130239239
    Abstract: The present invention provides LMCD1 cancer markers, and methods, compositions, and kits for their use. The invention also provides expression vectors, host cells, and transgenic animals comprising one or more LMCD1 mutations, and methods for their use in characterizing, diagnosing, and treating cancers, and for identifying potential therapeutics. The invention also provides cancer therapeutics.
    Type: Application
    Filed: March 7, 2012
    Publication date: September 12, 2013
    Inventors: Y-S Jou, C-Y Chang
  • Patent number: 8513027
    Abstract: The present invention provides for the treatment of primary headache disorders, particularly migraine, using antagonists of the EP4 receptor for prostaglandin E2. Particular EP4 receptor antagonists include azole compounds of formula (I): wherein R1 is a group such as lower alkyl substituted with carboxy; R2 is hydrogen or lower alkyl, R3 and R4 are aryl optionally substituted with halogen, Q is in which -A1- is a single bond or lower alkylene, is a cyclo group, -A3- is a single bond or lower alkylene, and X is O, NH or S; or a salt or its solvate thereof.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: August 20, 2013
    Assignee: Asterand UK Acquisition Limited
    Inventors: Gordon S. Baxter, Robert A. Coleman, Nicholas Tilford
  • Patent number: 8513028
    Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.
    Type: Grant
    Filed: May 8, 2007
    Date of Patent: August 20, 2013
    Assignee: Creagene Inc.
    Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
  • Patent number: 8512960
    Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: August 20, 2013
    Assignee: A&G Pharmaceutical, Inc.
    Inventor: Ginette Serrero
  • Patent number: 8492107
    Abstract: The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: July 23, 2013
    Assignees: University of Florida Research Foundation, Inc., Banyan Biomarkers, Inc.
    Inventors: Ka-Wang (Kevin) Wang, Ming-Cheng Liu, Monika Oli
  • Patent number: 8486657
    Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: July 16, 2013
    Inventors: Xiaohong Cai, Thomas Cai
  • Patent number: 8481276
    Abstract: Disclosed herein is a method for measuring the contractility of intestinal tissue upon treatment with GLP-2 or a GLP-2 ligand. Also disclosed is an assay which directly measures the activity of GLP-2 or GLP-2 ligands ex vivo and permits the screening of putative GLP-2 ligands in native tissue.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: July 9, 2013
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Lidia L. Demchyshyn, Hong Wang
  • Patent number: 8481277
    Abstract: Evaluation of VLP-I levels in combination with at least one of amyloid-? peptide (AB), hyperphosphorylated tau (pTau) or total tau (tTau) levels in samples of biological fluid improves the accuracy of diagnosis of Alzheimer's disease.
    Type: Grant
    Filed: August 21, 2008
    Date of Patent: July 9, 2013
    Assignee: Washington University
    Inventors: Jack H. Ladenson, Omar Laterza, Vijay Modur
  • Patent number: 8460881
    Abstract: A novel gene 254P1D6B and its encoded protein, and variants thereof, are described wherein 254P1D6B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 254P1D6B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 254P1D6B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 254P1D6B can be used in active or passive immunization.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: June 11, 2013
    Assignee: Agensys, Inc.
    Inventors: Arthur B. Raitano, Aya Jakobovits, Pia M. Challita-Eid, Wangmao Ge, Juan J. Perez-Villar, Steven B. Kanner
  • Patent number: 8450077
    Abstract: Materials and methods related to diagnosing a clinical condition in a subject, or determining the subject's predisposition to develop the clinical condition, using a multi-parameter system to measure a plurality of parameters and an algorithm to determine a disease score.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: May 28, 2013
    Assignee: Ridge Diagnostics, Inc.
    Inventors: Yiwu He, Bo Pi, John Bilello
  • Patent number: 8440395
    Abstract: The subject invention pertains to a method of detecting colon disorders including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, based on underexpression of Lipopolysaccharide Responsive Beige-like Anchor (LRBA). Advantageously, the invention may be used to test for inflammatory bowel disease using a blood sample from a subject before a more invasive test for colon disorders is employed. The invention also pertains to methods of treating a colon disorder in a subject in which the colon disorder is detected.
    Type: Grant
    Filed: October 10, 2009
    Date of Patent: May 14, 2013
    Assignee: University of South Florida
    Inventors: William G. Kerr, Joseph M. McKinley
  • Patent number: 8440418
    Abstract: Materials and methods for using combinations of metabolic syndrome and HPA axis biomarkers for monitoring major depressive disorder.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: May 14, 2013
    Assignee: Ridge Diagnostics, Inc.
    Inventors: John Bilello, Bo Pi
  • Patent number: 8404459
    Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: March 26, 2013
    Assignee: BioArctic Neuroscience AB
    Inventors: Pär Gellerfors, Lars Lannfelt
  • Patent number: 8399210
    Abstract: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: March 19, 2013
    Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-Universitat
    Inventors: Ugur Sahin, Özlem Türeci, Alexander Zaigler
  • Patent number: 8389227
    Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: March 5, 2013
    Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron
    Inventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
  • Patent number: 8383360
    Abstract: The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR).
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: February 26, 2013
    Assignee: The Regents of the University of California
    Inventors: Judy Van de Water, Daniel Braunschweig
  • Patent number: 8383349
    Abstract: The present invention relates to the use of proteins that are differentially expressed in tumor associated stromal cells, as compared to normal stromal, as biomolecular targets for tumor treatment therapies. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: February 26, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Hanson Zhen, Julie Sneddon, Patrick O. Brown, Anthony Oro
  • Patent number: 8367353
    Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: February 5, 2013
    Assignee: Roche MTM Laboratories AG
    Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
  • Patent number: 8367355
    Abstract: Disclosed are an antigen protein of black-lip pearl oyster egg extract, an antibody specific thereto, and a method of quantitative assessment of the reproductive effort of black-lip pearl oyster using the antibody. The method accomplishes quantitative assessment of reproductive effort of black-lip pearl oysters easily and accurately. In addition, the method provides important information for the study of life cycles of black-lip pearl oysters, and allows efficient management of black-lip pearl oysters.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: February 5, 2013
    Assignee: Korea Ocean Research And Development Institute
    Inventors: Do Hyung Kang, Kwang Sik Choi, Hee Do Jeoung, Heung Sik Park
  • Patent number: 8367344
    Abstract: Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: February 5, 2013
    Assignee: University of South Florida
    Inventor: Gary Willard Reuther
  • Patent number: 8357494
    Abstract: The invention concerns anti-clusterin oligoclonal antibodies able to recognize and bind in a selective and specific way antigenic epitopes of clusterin isoforms to be used in tumors diagnosis and in the prediction of their malignancy grade, diagnostic method and related kits.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: January 22, 2013
    Assignees: Universita' Delgi Studi “Tor Vergate”, Institute Fisioterapici Ospitalieri
    Inventors: Luigi Giusto Spagnoli, Sabina Pucci, Elena Bonanno, Flavia Pichiorri, Gennaro Citro
  • Patent number: 8354236
    Abstract: Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: January 15, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Virginia M. Y. Lee, John Q. Trojanowski
  • Patent number: 8333935
    Abstract: Disclosed is a microfluidic device including a microfluidic structure formed in a platform in which various examinations, such as an immune serum examination, can be automatically performed using the biomolecule microarray chip. The biomolecule microarray chip-type microfluidic device using a biomolecule microarray chip comprises: a platform which is rotatable; a microfluidic structure disposed in the platform, comprising: a plurality of chambers; a plurality of channels connecting the chambers each other; and a plurality of valves controlling flow of fluids through the channels, wherein the microfluidic structure controls flow of a fluid sample using rotation of the platform and the valves; and a biomolecule microarray chip mounted in the platform such that biomolecule capture probes bound to the biomolecule microarray chip contact the fluid sample in the microfluidic structure.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: December 18, 2012
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Beom-seok Lee, Jeong-gun Lee, Jong-myeon Park, Yoon-kyoung Cho
  • Patent number: 8309315
    Abstract: In a wide variety of human solid tumors, an aggressive, metastatic phenotype and poor clinical prognosis are associated with expression of the receptor tyrosine kinase Met. Disclosed herein are (a) a monoclonal antibody named Met4, which antibody is specific for Met, and (b) a hybridoma cell line that produces Met4. The Met4 antibody is particularly useful for detecting Met in formalin-fixed tissue. Methods of using the Met4 antibody for detection, diagnosis, prognosis, and evaluating therapeutic efficacy are provided.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: November 13, 2012
    Assignees: Van Andel Research Institute, Fred Hutchinson Cancer Research Center
    Inventors: Boliang Cao, George F. Vande Woude, Beatrice S. Knudsen, Ping Xu Zhao
  • Patent number: 8298784
    Abstract: An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: October 30, 2012
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Andreas Bergmann, Andrea Ernst, Harald Hampel